Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below 200-Day Moving Average – Here’s What Happened

Spero Therapeutics, Inc. (NASDAQ:SPRO)’s share price passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $2.31 and traded as low as $2.27. Spero Therapeutics shares last traded at $2.27, with a volume of 195,538 shares.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Wall Street Zen raised Spero Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, December 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Spero Therapeutics in a research note on Wednesday, October 8th. Finally, Zacks Research cut Spero Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 13th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Spero Therapeutics has an average rating of “Hold” and a consensus target price of $5.00.

Spero Therapeutics Stock Performance

The business has a 50 day simple moving average of $2.35 and a 200-day simple moving average of $2.31. The firm has a market cap of $127.89 million, a price-to-earnings ratio of -2.87 and a beta of 1.48.

Spero Therapeutics (NASDAQ:SPRO) last posted its earnings results on Thursday, November 13th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.12. Spero Therapeutics had a negative return on equity of 125.91% and a negative net margin of 108.11%.The company had revenue of $5.44 million for the quarter, compared to analyst estimates of $12.00 million. As a group, research analysts anticipate that Spero Therapeutics, Inc. will post -1.2 earnings per share for the current year.

Insider Buying and Selling

In other Spero Therapeutics news, insider Esther Rajavelu sold 40,270 shares of the business’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $2.37, for a total value of $95,439.90. Following the transaction, the insider owned 869,450 shares of the company’s stock, valued at approximately $2,060,596.50. The trade was a 4.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Spero Therapeutics

Large investors have recently made changes to their positions in the business. Invesco Ltd. purchased a new position in shares of Spero Therapeutics in the 2nd quarter worth about $43,000. Dimensional Fund Advisors LP purchased a new stake in Spero Therapeutics during the third quarter worth about $55,000. Quadrature Capital Ltd bought a new stake in shares of Spero Therapeutics in the 2nd quarter worth approximately $90,000. Axxcess Wealth Management LLC purchased a new stake in Spero Therapeutics in the 2nd quarter worth about $94,000. Finally, Capital Asset Advisory Services LLC bought a new position in Spero Therapeutics in the 2nd quarter worth approximately $94,000. 25.60% of the stock is owned by hedge funds and other institutional investors.

About Spero Therapeutics

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.